GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bluejay Diagnostics BJDX · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.49

+5.96%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2019FY2025

Net income

−$6.8m

FY2019FY2025

Free cash flow

−$6.2m

FY2019FY2025

Shareholders' equity

$6.0m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue———$249,040$75——
Gross profit−$170,681−$199,097−$780,955$48,911−$145,719−$157,039−$142,975
Research and development$3.0m$3.5m$5.7m$4.2m$1.1m$527,253$454,610
Operating income−$7.0m−$7.2m−$10.3m−$9.3m−$3.2m−$1.2m−$1.6m
Net income−$6.8m−$7.7m−$10.0m−$9.3m−$3.7m−$1.1m−$757,716
Diluted earnings per share-15.25-192.46-257.21-294.21-118.78-56.85-0.36

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$7.1m$6.7m$4.9m$13.5m$21.0m$1.5m$916,518
Cash and short-term investments$5.2m$4.3m$2.2m$10.1m$19.0m$912,361$96,011
Total liabilities$1.1m$927,924$2.0m$2.0m$637,162$5.7m$3.8m
Debt$120,211$222,249$352,977$492,621—$1.1m$1.1m
Shareholders' equity$6.0m$5.7m$2.9m$11.5m$20.4m−$4.2m−$2.9m
Shares outstanding0m0m0m0m0m0m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$6.1m−$7.8m−$8.3m−$7.7m−$4.4m−$508,710−$1.7m
Capital spending−$173,735−$306,783−$704,166−$1.2m−$23,947−$23,947−$6,021
Free cash flow−$6.2m−$8.1m−$9.0m−$8.9m−$4.4m−$532,657−$1.7m
Dividends paid————−$17,667——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—————$216,086$216,086—
Gross profit—−$49,558−$48,809−$31,624−$38,355−$51,893$108,043−$53,572
Operating income−$2.3m−$1.9m−$1.5m−$1.6m−$2.0m−$1.9m−$1.5m−$1.4m
Net income−$2.3m−$1.9m−$1.4m−$1.6m−$2.0m−$1.9m−$1.4m−$1.5m
Diluted earnings per share-1.12-0.92-3.18-3.56-4.36-4.15-35.71-36.96
Cash from operations−$1.0m−$1.0m−$1.0m−$1.0m−$2.0m−$1.0m−$1.0m−$1.0m
Total assets$11.5m$5.6m$7.1m$4.9m$6.4m$5.3m$6.7m$8.4m
Cash and short-term investments$9.6m$3.7m$5.2m$3.1m$4.4m$3.1m$4.3m$5.8m
Debt$78,251$97,032$100,000$100,000$104,809$100,000$113,260$111,453
Shareholders' equity$9.4m$4.2m$6.0m$3.7m$5.3m$3.9m$5.7m$7.2m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-9.3%42.2%—
Net income-9.7%43.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.3-0.1-2.7-14.7-245.4

Share price return

Finished calendar years

20252024202320222021
Return-46%-99%-67%-85%-42%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 4-to-1 reverse split · 3 Nov 2026
  • 4-to-1 reverse split · 29 Jan 2026
  • 50-to-1 reverse split · 18 Nov 2024
  • 8-to-1 reverse split · 20 Jun 2024
  • 20-to-1 reverse split · 24 Jul 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.